Viral suppression, virological failure and change in CD4 cell count at 24 and 48 weeks from ART initiation according to first-line antiretroviral regimen, CoRIS cohort, 2018–2021
| . | . | DTG/3TC n = 401 . | 3DR-InSTI n = 1759 . | BIC/FTC/TAF n = 949 . | DTG/3TC/ABC n = 255 . | DRV/COBI/FTC/TAF n = 147 . | EVG/COBI/FTC/TAF n = 126 . | DTG + FTC/TDF n = 282 . |
|---|---|---|---|---|---|---|---|---|
| Viral suppression | ||||||||
| Individuals included, n (%) | Week 24 | 266 (66.3) | 1149 (71.3) | 646 (68.1) | 189 (74.1) | 122 (83.0) | 102 (81.0) | 212 (75.2) |
| Week 48 | 160 (39.9) | 873 (54.2) | 446 (47.0) | 173 (67.8) | 87 (59.2) | 92 (73.0) | 162 (57.4) | |
| Viral suppression, n (%) | Week 24 | 243 (91.4) | 962 (83.7) | 537 (83.1) | 158 (83.6) | 91 (74.6) | 92 (90.2) | 175 (82.5) |
| Week 48 | 150 (93.8) | 781 (89.5) | 395 (88.6) | 157 (90.8) | 75 (86.2) | 87 (94.6) | 142 (87.7) | |
| Virological failure | ||||||||
| Individuals included, n (%) | Week 24 | 143 (35.7) | 305 (32.1) | 104 (40.8) | 30 (20.4) | 45 (35.7) | 119 (42.2) | |
| Week 48 | 197 (49.1) | 478 (50.4) | 167 (65.5) | 75 (51.0) | 88 (69.8) | 172 (61.0) | ||
| Virological failure, n (%) | Week 24 | 2 (1.4) | 2 (0.7) | 2 (1.9) | 2 (6.7) | 1 (2.2) | 2 (1.7) | |
| Week 48 | 3 (1.5) | 8 (1.7) | 5 (3.0) | 2 (2.7) | 2 (2.3) | 5 (2.9) | ||
| Change in CD4 cell count | ||||||||
| Mean (95% CI) CD4 count at ART initiation (cells/µL) | 390.0 (376.5–403.5) | 372.6 (355.5–389.7) | 447.3 (413.2–481.4) | 388.5 (338.8–438.2) | 475.1 (411.8–538.4) | 357.4 (328.2–386.7) | 390.0 (376.5–403.5) | |
| Individuals included, n (%) | Week 24 | 267 (66.6) | 1019 (63.2) | 563 (59.3) | 175 (68.6) | 110 (74.8) | 91 (72.2) | 190 (67.4) |
| Week 48 | 156 (38.9) | 789 (48.9) | 391 (41.2) | 160 (62.7) | 80 (54.4) | 82 (65.1) | 156 (55.3) | |
| Mean change (95% CI) in CD4 count | Week 24 | 205.7 (181.1; 230.2) | 206.6 (193.9; 219.2) | 201.4 (184.3; 218.4) | 202.0 (173.7; 230.3) | 187.5 (150.2; 224.7) | 179.9 (131.5; 228.3) | 238.9 (209.9; 267.9) |
| Week 48 | 258.6 (224.0; 293.2) | 258.3 (242.8; 273.8) | 244.8 (223.3; 266.3) | 264.7 (229.8; 299.7) | 246.0 (198.8; 293.2) | 269.7 (221.1; 318.3) | 279.5 (242.7; 316.3) | |
| . | . | DTG/3TC n = 401 . | 3DR-InSTI n = 1759 . | BIC/FTC/TAF n = 949 . | DTG/3TC/ABC n = 255 . | DRV/COBI/FTC/TAF n = 147 . | EVG/COBI/FTC/TAF n = 126 . | DTG + FTC/TDF n = 282 . |
|---|---|---|---|---|---|---|---|---|
| Viral suppression | ||||||||
| Individuals included, n (%) | Week 24 | 266 (66.3) | 1149 (71.3) | 646 (68.1) | 189 (74.1) | 122 (83.0) | 102 (81.0) | 212 (75.2) |
| Week 48 | 160 (39.9) | 873 (54.2) | 446 (47.0) | 173 (67.8) | 87 (59.2) | 92 (73.0) | 162 (57.4) | |
| Viral suppression, n (%) | Week 24 | 243 (91.4) | 962 (83.7) | 537 (83.1) | 158 (83.6) | 91 (74.6) | 92 (90.2) | 175 (82.5) |
| Week 48 | 150 (93.8) | 781 (89.5) | 395 (88.6) | 157 (90.8) | 75 (86.2) | 87 (94.6) | 142 (87.7) | |
| Virological failure | ||||||||
| Individuals included, n (%) | Week 24 | 143 (35.7) | 305 (32.1) | 104 (40.8) | 30 (20.4) | 45 (35.7) | 119 (42.2) | |
| Week 48 | 197 (49.1) | 478 (50.4) | 167 (65.5) | 75 (51.0) | 88 (69.8) | 172 (61.0) | ||
| Virological failure, n (%) | Week 24 | 2 (1.4) | 2 (0.7) | 2 (1.9) | 2 (6.7) | 1 (2.2) | 2 (1.7) | |
| Week 48 | 3 (1.5) | 8 (1.7) | 5 (3.0) | 2 (2.7) | 2 (2.3) | 5 (2.9) | ||
| Change in CD4 cell count | ||||||||
| Mean (95% CI) CD4 count at ART initiation (cells/µL) | 390.0 (376.5–403.5) | 372.6 (355.5–389.7) | 447.3 (413.2–481.4) | 388.5 (338.8–438.2) | 475.1 (411.8–538.4) | 357.4 (328.2–386.7) | 390.0 (376.5–403.5) | |
| Individuals included, n (%) | Week 24 | 267 (66.6) | 1019 (63.2) | 563 (59.3) | 175 (68.6) | 110 (74.8) | 91 (72.2) | 190 (67.4) |
| Week 48 | 156 (38.9) | 789 (48.9) | 391 (41.2) | 160 (62.7) | 80 (54.4) | 82 (65.1) | 156 (55.3) | |
| Mean change (95% CI) in CD4 count | Week 24 | 205.7 (181.1; 230.2) | 206.6 (193.9; 219.2) | 201.4 (184.3; 218.4) | 202.0 (173.7; 230.3) | 187.5 (150.2; 224.7) | 179.9 (131.5; 228.3) | 238.9 (209.9; 267.9) |
| Week 48 | 258.6 (224.0; 293.2) | 258.3 (242.8; 273.8) | 244.8 (223.3; 266.3) | 264.7 (229.8; 299.7) | 246.0 (198.8; 293.2) | 269.7 (221.1; 318.3) | 279.5 (242.7; 316.3) | |
DTG/3TC, dolutegravir/lamivudine; 3DR-InSTI, three-drug regimen including integrase inhibitor (BIC/FTC/TAF, DTG/3TC/ABC, EVG/COBI/FTC/TAF and DTG + FTC/TDF); BIC/FTC/TAF, bictegravir/emtricitabine/tenofovir alafenamide; DTG/3TC/ABC, dolutegravir/lamivudine/abacavir; DRV/COBI/FTC/TAF, darunavir/cobicistat/emtricitabine/tenofovir alafenamide; EVG/COBI/FTC/TAF, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; DTG + FTC/TDF, dolutegravir + emtricitabine/tenofovir disoproxil fumarate.
Viral suppression, virological failure and change in CD4 cell count at 24 and 48 weeks from ART initiation according to first-line antiretroviral regimen, CoRIS cohort, 2018–2021
| . | . | DTG/3TC n = 401 . | 3DR-InSTI n = 1759 . | BIC/FTC/TAF n = 949 . | DTG/3TC/ABC n = 255 . | DRV/COBI/FTC/TAF n = 147 . | EVG/COBI/FTC/TAF n = 126 . | DTG + FTC/TDF n = 282 . |
|---|---|---|---|---|---|---|---|---|
| Viral suppression | ||||||||
| Individuals included, n (%) | Week 24 | 266 (66.3) | 1149 (71.3) | 646 (68.1) | 189 (74.1) | 122 (83.0) | 102 (81.0) | 212 (75.2) |
| Week 48 | 160 (39.9) | 873 (54.2) | 446 (47.0) | 173 (67.8) | 87 (59.2) | 92 (73.0) | 162 (57.4) | |
| Viral suppression, n (%) | Week 24 | 243 (91.4) | 962 (83.7) | 537 (83.1) | 158 (83.6) | 91 (74.6) | 92 (90.2) | 175 (82.5) |
| Week 48 | 150 (93.8) | 781 (89.5) | 395 (88.6) | 157 (90.8) | 75 (86.2) | 87 (94.6) | 142 (87.7) | |
| Virological failure | ||||||||
| Individuals included, n (%) | Week 24 | 143 (35.7) | 305 (32.1) | 104 (40.8) | 30 (20.4) | 45 (35.7) | 119 (42.2) | |
| Week 48 | 197 (49.1) | 478 (50.4) | 167 (65.5) | 75 (51.0) | 88 (69.8) | 172 (61.0) | ||
| Virological failure, n (%) | Week 24 | 2 (1.4) | 2 (0.7) | 2 (1.9) | 2 (6.7) | 1 (2.2) | 2 (1.7) | |
| Week 48 | 3 (1.5) | 8 (1.7) | 5 (3.0) | 2 (2.7) | 2 (2.3) | 5 (2.9) | ||
| Change in CD4 cell count | ||||||||
| Mean (95% CI) CD4 count at ART initiation (cells/µL) | 390.0 (376.5–403.5) | 372.6 (355.5–389.7) | 447.3 (413.2–481.4) | 388.5 (338.8–438.2) | 475.1 (411.8–538.4) | 357.4 (328.2–386.7) | 390.0 (376.5–403.5) | |
| Individuals included, n (%) | Week 24 | 267 (66.6) | 1019 (63.2) | 563 (59.3) | 175 (68.6) | 110 (74.8) | 91 (72.2) | 190 (67.4) |
| Week 48 | 156 (38.9) | 789 (48.9) | 391 (41.2) | 160 (62.7) | 80 (54.4) | 82 (65.1) | 156 (55.3) | |
| Mean change (95% CI) in CD4 count | Week 24 | 205.7 (181.1; 230.2) | 206.6 (193.9; 219.2) | 201.4 (184.3; 218.4) | 202.0 (173.7; 230.3) | 187.5 (150.2; 224.7) | 179.9 (131.5; 228.3) | 238.9 (209.9; 267.9) |
| Week 48 | 258.6 (224.0; 293.2) | 258.3 (242.8; 273.8) | 244.8 (223.3; 266.3) | 264.7 (229.8; 299.7) | 246.0 (198.8; 293.2) | 269.7 (221.1; 318.3) | 279.5 (242.7; 316.3) | |
| . | . | DTG/3TC n = 401 . | 3DR-InSTI n = 1759 . | BIC/FTC/TAF n = 949 . | DTG/3TC/ABC n = 255 . | DRV/COBI/FTC/TAF n = 147 . | EVG/COBI/FTC/TAF n = 126 . | DTG + FTC/TDF n = 282 . |
|---|---|---|---|---|---|---|---|---|
| Viral suppression | ||||||||
| Individuals included, n (%) | Week 24 | 266 (66.3) | 1149 (71.3) | 646 (68.1) | 189 (74.1) | 122 (83.0) | 102 (81.0) | 212 (75.2) |
| Week 48 | 160 (39.9) | 873 (54.2) | 446 (47.0) | 173 (67.8) | 87 (59.2) | 92 (73.0) | 162 (57.4) | |
| Viral suppression, n (%) | Week 24 | 243 (91.4) | 962 (83.7) | 537 (83.1) | 158 (83.6) | 91 (74.6) | 92 (90.2) | 175 (82.5) |
| Week 48 | 150 (93.8) | 781 (89.5) | 395 (88.6) | 157 (90.8) | 75 (86.2) | 87 (94.6) | 142 (87.7) | |
| Virological failure | ||||||||
| Individuals included, n (%) | Week 24 | 143 (35.7) | 305 (32.1) | 104 (40.8) | 30 (20.4) | 45 (35.7) | 119 (42.2) | |
| Week 48 | 197 (49.1) | 478 (50.4) | 167 (65.5) | 75 (51.0) | 88 (69.8) | 172 (61.0) | ||
| Virological failure, n (%) | Week 24 | 2 (1.4) | 2 (0.7) | 2 (1.9) | 2 (6.7) | 1 (2.2) | 2 (1.7) | |
| Week 48 | 3 (1.5) | 8 (1.7) | 5 (3.0) | 2 (2.7) | 2 (2.3) | 5 (2.9) | ||
| Change in CD4 cell count | ||||||||
| Mean (95% CI) CD4 count at ART initiation (cells/µL) | 390.0 (376.5–403.5) | 372.6 (355.5–389.7) | 447.3 (413.2–481.4) | 388.5 (338.8–438.2) | 475.1 (411.8–538.4) | 357.4 (328.2–386.7) | 390.0 (376.5–403.5) | |
| Individuals included, n (%) | Week 24 | 267 (66.6) | 1019 (63.2) | 563 (59.3) | 175 (68.6) | 110 (74.8) | 91 (72.2) | 190 (67.4) |
| Week 48 | 156 (38.9) | 789 (48.9) | 391 (41.2) | 160 (62.7) | 80 (54.4) | 82 (65.1) | 156 (55.3) | |
| Mean change (95% CI) in CD4 count | Week 24 | 205.7 (181.1; 230.2) | 206.6 (193.9; 219.2) | 201.4 (184.3; 218.4) | 202.0 (173.7; 230.3) | 187.5 (150.2; 224.7) | 179.9 (131.5; 228.3) | 238.9 (209.9; 267.9) |
| Week 48 | 258.6 (224.0; 293.2) | 258.3 (242.8; 273.8) | 244.8 (223.3; 266.3) | 264.7 (229.8; 299.7) | 246.0 (198.8; 293.2) | 269.7 (221.1; 318.3) | 279.5 (242.7; 316.3) | |
DTG/3TC, dolutegravir/lamivudine; 3DR-InSTI, three-drug regimen including integrase inhibitor (BIC/FTC/TAF, DTG/3TC/ABC, EVG/COBI/FTC/TAF and DTG + FTC/TDF); BIC/FTC/TAF, bictegravir/emtricitabine/tenofovir alafenamide; DTG/3TC/ABC, dolutegravir/lamivudine/abacavir; DRV/COBI/FTC/TAF, darunavir/cobicistat/emtricitabine/tenofovir alafenamide; EVG/COBI/FTC/TAF, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; DTG + FTC/TDF, dolutegravir + emtricitabine/tenofovir disoproxil fumarate.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
